Company Overview - Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders [2] - The company is advancing verekitug, a monoclonal antibody targeting the receptor for thymic stromal lymphopoietin, which is involved in inflammatory responses [2] - Verekitug is currently in separate Phase 2 trials for severe asthma and chronic rhinosinusitis with nasal polyps, with plans to initiate development for chronic obstructive pulmonary disease [2] Upcoming Events - Rand Sutherland, MD, CEO of Upstream Bio, will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, from 11:50 a.m. to 12:20 p.m. ET [3] - The company will also participate in the Leerink Partners Global Biopharma Conference on March 12, 2025, from 1:40 p.m. to 2:10 p.m. ET [3] - A live webcast of the presentations will be available on the company's website, with replays posted afterward [1]
Upstream Bio to Present at Upcoming March Investor Conferences